Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Non-Current Assets: 2019-2024

Historic Non-Current Assets for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to $15.3 million.

  • Silence Therapeutics' Non-Current Assets fell 14.69% to $13.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.6 million, marking a year-over-year decrease of 2.88%. This contributed to the annual value of $15.3 million for FY2024, which is 6.31% down from last year.
  • Silence Therapeutics' Non-Current Assets amounted to $15.3 million in FY2024, which was down 6.31% from $16.3 million recorded in FY2023.
  • Silence Therapeutics' Non-Current Assets' 5-year high stood at $16.3 million during FY2023, with a 5-year trough of $12.3 million in FY2020.
  • Its 3-year average for Non-Current Assets is $15.0 million, with a median of $15.3 million in 2024.
  • Per our database at Business Quant, Silence Therapeutics' Non-Current Assets grew by 21.78% in 2023 and then decreased by 6.31% in 2024.
  • Silence Therapeutics' Non-Current Assets (MRY) stood at $12.3 million in 2020, then grew by 10.38% to $13.6 million in 2021, then dropped by 1.36% to $13.4 million in 2022, then increased by 21.78% to $16.3 million in 2023, then fell by 6.31% to $15.3 million in 2024.
  • Its last three reported values are $15.3 million in FY2024, $16.3 million for FY2023, and $13.4 million during FY2022.